Drug Trial Radar · NCT05151731
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
394
Actual
Start
Dec 31, 2021
Primary completion
Nov 6, 2024
Study completion Apr 21, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study BP43445 is a phase II, multicenter, randomized, double-masked, active comparator-controlled study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of vamikibart administered intravitreally in participants with diabetic macular edema. Only one eye will be chosen as the study eye. The duration of the study will be up to 76 weeks.
Conditions
- Diabetic Macular Edema
Interventions
VamikibartDrug
Vamikibart will be administered by IVT injection as specified in each treatment arm.
RanibizumabDrug
Ranibizumab 0.5 mg will be administered to the participants by IVT injection, as specified in the treatment arm.
Sham ProcedureOther
Sham is a procedure that mimics an IVT injection and involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. Sham procedure will be administered to participants in the Q8W arms at applicable visits to maintain masking between treatment arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Best-Corrected Visual Acuity (BCVA) Averaged Over Week 44 and Week 48, in Treatment-naïve ParticipantsTime frame: Baseline, Weeks 44 and 48
Locations
74 sites in 9 countries. Site status is shown where the registry gives one.
Win Retina
Arcadia, California
Retina Consultants, San Diego
Poway, California
Retinal Consultants Med Group
Sacramento, California
Bay Area Retina Associates
Walnut Creek, California
Colorado Retina Associates, PC
Lakewood, Colorado
Emerson Clinical Research Institute LLC
Washington D.C., District of Columbia
Rand Eye
Deerfield Beach, Florida
National Ophthalmic Research Institute
Fort Myers, Florida
Florida Retina Institute
Orlando, Florida
Retina Vitreous Associates of Florida
St. Petersburg, Florida
Retina Specialists of Tampa
Wesley Chapel, Florida
Butchertown Clinical Trials
Louisville, Kentucky
Cumberland Valley Retina PC
Hagerstown, Maryland
Deep Blue Retina PLLC
Southaven, Mississippi
Sierra Eye Associates
Reno, Nevada
Opthalmic Consultants of LI
Lynbrook, New York
University of Rochester Flaum Eye Institute
Rochester, New York
Western Carolina Retinal Associate PA
Asheville, North Carolina
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Meridian Clinical Research
Cincinnati, Ohio
Verum Research LLC
Eugene, Oregon
EyeHealth Northwest
Portland, Oregon
Erie Retinal Surgery
Erie, Pennsylvania
Eye Care Specialists, PC
Kingston, Pennsylvania
Sewickley Eye Group
Sewickley, Pennsylvania
Charleston Neuroscience Institute
Ladson, South Carolina
Black Hills Eye Institute
Rapid City, South Dakota
Retina Consultants of Nashville
Nashville, Tennessee
Texas Retina Associates
Arlington, Texas
Austin Clinical Research LLC
Austin, Texas
Retina Consultants of Texas
Bellaire, Texas
Valley Retina Institute P.A.
McAllen, Texas
Retina Consultants of Texas
The Woodlands, Texas
Strategic Clinical Research Group, LLC
Willow Park, Texas
Piedmont Eye Center
Lynchburg, Virginia
Wagner Macula & Retina Center
Norfolk, Virginia
Organizacion Medica de Investigacion
Buenos Aires, Argentina
Centro Oftalmologico Dr. Charles S.A.
Capital Federal, Argentina
Oftalmos
Capital Federal, Argentina
Buenos Aires Mácula
Ciudad Autonoma Buenos Aires, Argentina
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.